Home etftrends.com Despite Lyft, Uber Struggles, IPO ETF Performed Well in 2019

Despite Lyft, Uber Struggles, IPO ETF Performed Well in 2019

Advertisement
Digital Marketing & Website Design for ETFs

With just a few days left in 2019, it’s fair to say some of this year’s most ballyhooed initial public offerings, such as Lyft (NASDAQ: LYFT) and Uber (NYSE: UBER), disappointed investors. It’s also fair to say the  Renaissance IPO ETF (NYSEArca: IPO) has been anything but disappointing as that ETF is higher by almost 34% as of Dec. 24.

IPO tracks the rules-based Renaissance IPO Index, which adds sizeable new companies on a fast entry basis and the rest upon scheduled quarterly reviews. Companies that have been public for two years are removed at the next quarterly review.

Additionally, the Renaissance IPO ETF is the only ETF focusing exclusively on the U.S. IPO Market. Renaissance Capital believes that IPO reinvents IPO investing by providing access to the U.S. IPO Market through an ETF, without investors having to buy IPOs individually.

“Renaissance Capital’s IPO Index, a basket of newly public companies, is up 33% this year versus a 29% rise in S&P 500,” reports CNBC. “More than half of newly listed companies were trading above their issue price at the end of the year, compared with about 40% last year, according to Renaissance Capital, which provides institutional research and IPO ETFs.”

Riding Along With This IPO

Ridesharing IPOs like Lyft and Uber may have sputtered off the starting line, but some IPOs like Slack are getting rave reviews from market analysts keeping an eye out on the latest offerings from Silicon Valley. Investors who haven’t warmed up to allocating capital into the IPO space can dip their toes in the water with exchange-traded funds (ETFs).

“Health-care and technology companies were the best performers for the fifth year in a row. Karuna Therapeutics took the top spot with a roughly 380% gain year to date,” reports CNBC. “Smith pointed to the FDA approving new immunotherapy and cancer drugs ‘faster than investors thought.’ Medical device companies also performed well and were widely seen as M&A targets, according to Smith.”

As of Oct. 31, IPO had a healthcare weight of 10.5%, according to Renaissance Capital data.

For more investing strategies, visit our Equity ETF Channel.

The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.

newETFs.io respects the hard work of others and gives all credit to the remarkable folks at ETFTrends.com. This excerpt/article was pulled from their RSS feed; click here to view the original. Please note that on occasion, the RSS feed will not have the author. When this happens this site defaults the author to "News". Make no mistake, this excerpt/article was not created by newETFs.io, it was simply shared with you.